Ken Griffin Increases Stake in AbbVie and Abbott Laboratories
Billionaire Ken Griffin, founder of Citadel, has increased his holdings in AbbVie (ABBV) and Abbott Laboratories (ABT), according to a recent 13F filing. The move highlights his confidence in the healthcare sector's resilience across market conditions. AbbVie is transitioning from its Humira legacy into immunology with drugs like Skyrizi and Rinvoq, while also expanding into oncology through acquisitions such as ImmunoGen. Abbott Laboratories focuses on medical devices and diagnostics, including glucose monitors and lab equipment, which are seeing strong demand globally. Both companies offer a mix of stable cash flows and growth potential. Investors may view Griffin's increased exposure to these firms as an endorsement of their long-term strategies in healthcare innovation and market diversification.
Topics: Abbott Laboratories AbbVie healthcare hedge_fund_activity